Skin Cancer for Dental Professionals
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
In Dermatology Visit with Me to Discuss
From time to time new treatments surface for any medical field, and the last couple of years have seen new treatments emerge, or new applications for familiar treatments. I wanted to summarize some of these New Therapies widely available remedies and encourage you to schedule a in Dermatology visit with me to discuss. Written by Board Certified Dermatologist James W. Young, DO, FAOCD Nicotinamide a significant reduction in melanoma in Antioxidants Nicotinamide (niacinamide) is a form high risk skin cancer patients at doses Green tea, pomegranate, delphinidin of vitamin B3. The deficiency of vitamin more than 600 and less than 4,000 IU and fisetin are all under current study for daily. B3 causes pellagra, a condition marked either oral or topical use in the reduction by 4D’s – (photo) Dermatitis, Dementia, Polypodium Leucotomos of the incidence of skin cancer, psoriasis Diarrhea and (if left untreated) Death. and other inflammatory disorders. I’ll be Polypodium leucotomos is a Central This deficiency is rare in developed sure to keep patients updated. countries, but is occasionally seen America fern that is available in several in alcoholism, dieting restrictions, or forms, most widely as Fernblock What Are My Own Thoughts? malabsorption syndromes. Nicotinamide (Amazon) or Heliocare (Walgreen’s and I take Vitamin D 1,000 IU and Heliocare does not cause the adverse effects of Amazon) and others. It is an antioxidant personally. Based on new research, I Nicotinic acid and is safe at doses up to that reduces free oxygen radicals and have also added Nicotinamide which 3,000mg daily. may reduce inflammation in eczema, dementia, sunburn, psoriasis, and vitiligo. -
What Is Acne? Acne Is a Disease of the Skin's Sebaceous Glands
What is Acne? Acne is a disease of the skin’s sebaceous glands. Sebaceous glands produce oils that carry dead skin cells to the surface of the skin through follicles. When a follicle becomes clogged, the gland becomes inflamed and infected, producing a pimple. Who Gets Acne? Acne is the most common skin disease. It is most prevalent in teenagers and young adults. However, some people in their forties and fifties still get acne. What Causes Acne? There are many factors that play a role in the development of acne. Some of these include hormones, heredity, oil based cosmetics, topical steroids, and oral medications (corticosteroids, lithium, iodides, some antiepileptics). Some endocrine disorders may also predispose patients to developing acne. Skin Care Tips: Clean skin gently using a mild cleanser at least twice a day and after exercising. Scrubbing the skin can aggravate acne, making it worse. Try not to touch your skin. Squeezing or picking pimples can cause scars. Males should shave gently and infrequently if possible. Soften your beard with soap and water before putting on shaving cream. Avoid the sun. Some acne treatments will cause skin to sunburn more easily. Choose oil free makeup that is “noncomedogenic” which means that it will not clog pores. Shampoo your hair daily especially if oily. Keep hair off your face. What Makes Acne Worse? The hormone changes in females that occur 2 to 7 days prior to period starting each month. Bike helmets, backpacks, or tight collars putting pressure on acne prone skin Pollution and high humidity Squeezing or picking at pimples Scrubs containing apricot seeds. -
What Is Acne and Why Do I Have Pimples?
What is acne and why do I have pimples? The medical term for “pimples” is acne. Most people develop at least some acne, especially during their teenage years. Although many believe that acne comes from being dirty, this is not true; rather, acne is the result of changes that occur during puberty. Your skin is made of layers. To keep the skin from getting dry, the skin makes oil in little wells called “sebaceous glands” that are found in the deeper layers of the skin. “Whiteheads” or “blackheads” are clogged sebaceous glands. “Blackheads” are not caused by dirt blocking the pores, but rather by oxidation (a chemical reaction that occurs when the oil reacts with oxygen in the air). People with acne have glands that make more oil and are more easily plugged, causing the glands to swell. Hormones, bacteria (called P. acnes) and your family’s likelihood to have acne (genetic susceptibility) also play a role. SKIN HYGIENE Good skin care habits are important and support the medications your doctor prescribes for your acne. » Wash your face twice a day, once in the morning and once in the evening (which includes any showers you take). » Avoid over-washing/over-scrubbing your face as this will not improve the acne and may lead to dryness and irritation, which can interfere with your medications. » In general, milder soaps and cleansers are better for acne-prone skin. The soaps labeled “for sensitive skin” are milder than those labeled “deodorant soap” or “antibacterial soap.” » Many “acne washes” may contain salicylic acid. Salicylic acid (SA) fights oil and bacteria mildly but can be drying and can add to irritation. -
Pilar Sheath Acanthoma Presenting As a Nevus
Letter to Editor Pilar Sheath Acanthoma Presenting as a Nevus Sir, Pilar sheath acanthoma (PSA) is a rare benign follicular neoplasm, which was first described by Mehregan and Brownstein in 1978.[1] PSA usually presents as an asymptomatic, flesh colored papule with a central opening localized at the lower lip with exceptional presentations such as ear lobe, postauricular region, or cheek.[1‑3] A 42‑year‑old female referred with a solitary, slow‑growing nodular lesion at the upper lip region for 6 months. Physical exam revealed a 4 mm, pink‑brown colored nodule with a central opening [Figure 1]. Under clinical prediagnosis of melanocytic nevus, an excisional biopsy Figure 1: Physical examination of the nodule in the upper lip region was performed. In a microscopic examination, a cystic cavity that communicated with surface epidermis has been observed. The wall of the cystic cavity was composed of solid tumor islands extending in the deep dermis [Figure 2]. The cavity was lined with stratified squamous epithelium filled with keratin [Figure 3]. PSA is an uncommon, benign follicular tumor occurring in the faces of middle‑aged and elderly patients. These lesions can present at any location such as cheek, ear lobe on the head, and neck. In our case, a 42‑year‑old female was presented with a pink‑brown colored nodular lesion opening at the upper lip region. The differential diagnosis includes trichofolliculoma and dilated pore of Winer. Trichofolliculomas contain many seconder hair follicles Figure 2: A central cavity with keratin in the dermis which is continuous radiating from the wall of the primary follicle with outer with the surface epithelium (H and E, ×40) and inner root sheaths in a well‑formed stroma which are absent in PSA. -
Actinic Keratoses Final Report
Actinic Keratoses Final Report Mark Helfand, MD, MPH Annalisa K. Gorman, MD Susan Mahon, MPH Benjamin K.S. Chan, MS Neil Swanson, MD Submitted to the Agency for Healthcare Research and Quality under contract 290-97-0018, task order no. 6 Oregon Health & Science University Evidence-based Practice Center 3181 SW Sam Jackson Park Road Portland, Oregon 97201 May 19, 2001 Actinic Keratoses Structured Abstract Objective: To examine evidence about the natural history and management of actinic keratoses (AKs). Search Strategy: We searched the MEDLINE database from January 1966 to January 2001, the Cochrane Controlled Trials Registry, and a bibliographic database of articles about skin cancer. We identified additional articles from reference lists and experts. Selection Criteria: We selected 45 articles that contained original data relevant to treatment of actinic keratoses, progression of AKs to squamous cell cancer (SCC ), means of identifying a high-risk group, or surveillance of patients with AKs to detect and treat SCCs early in their course. Data Collection and Analysis: We abstracted information from these studies to construct evidence tables. We also developed a simple mathematical model to examine whether estimates of the rate of progression of AK to SCC were consistent among studies. Finally, we analyzed data from the Medicare Statistical System to estimate the frequency of procedures attributable to AK among elderly beneficiaries. Main Results: The yearly rate of progression of an AK in an average-risk person in Australia is between 8 and 24 per 10,000. High-risk individuals with multiple AKs have progression rates as high as 12-30 percent over 3 years. -
What Are Basal and Squamous Cell Skin Cancers?
cancer.org | 1.800.227.2345 About Basal and Squamous Cell Skin Cancer Overview If you have been diagnosed with basal or squamous cell skin cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Basal and Squamous Cell Skin Cancers? Research and Statistics See the latest estimates for new cases of basal and squamous cell skin cancer and deaths in the US and what research is currently being done. ● Key Statistics for Basal and Squamous Cell Skin Cancers ● What’s New in Basal and Squamous Cell Skin Cancer Research? What Are Basal and Squamous Cell Skin Cancers? Basal and squamous cell skin cancers are the most common types of skin cancer. They start in the top layer of skin (the epidermis), and are often related to sun exposure. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer cells. To learn more about cancer and how it starts and spreads, see What Is Cancer?1 Where do skin cancers start? Most skin cancers start in the top layer of skin, called the epidermis. There are 3 main types of cells in this layer: ● Squamous cells: These are flat cells in the upper (outer) part of the epidermis, which are constantly shed as new ones form. When these cells grow out of control, they can develop into squamous cell skin cancer (also called squamous cell carcinoma). -
Sunburn, Suntan and the Risk of Cutaneous Malignant Melanoma the Western Canada Melanoma Study J.M
Br. J. Cancer (1985), 51, 543-549 Sunburn, suntan and the risk of cutaneous malignant melanoma The Western Canada Melanoma Study J.M. Elwood1, R.P. Gallagher2, J. Davison' & G.B. Hill3 1Department of Community Health, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK; 2Division of Epidemiology and Biometry, Cancer Control Agency of British Columbia, 2656 Heather Street, Vancouver BC, Canada V5Z 3J3; and 3Department of Epidemiology, Alberta Cancer Board, Edmonton, Alberta, Canada T6G OTT2. Summary A comparison of interview data on 595 patients with newly incident cutaneous melanoma, excluding lentigo maligna melanoma and acral lentiginous melanoma, with data from comparison subjects drawn from the general population, showed that melanoma risk increased in association with the frequency and severity of past episodes of sunburn, and also that melanoma risk was higher in subjects who usually had a relatively mild degree of suntan compared to those with moderate or deep suntan in both winter and summer. The associations with sunburn and with suntan were independent. Melanoma risk is also increased in association with a tendency to burn easily and tan poorly and with pigmentation characteristics of light hair and skin colour, and history freckles; the associations with sunburn and suntan are no longer significant when these other factors are taken into account. This shows that pigmentation characteristics, and the usual skin reaction to sun, are more closely associated with melanoma risk than are sunburn and suntan histories. -
Thrombotic Thrombocytopenic Purpura Due to Checkpoint Inhibitors
Hindawi Case Reports in Hematology Volume 2018, Article ID 2464619, 4 pages https://doi.org/10.1155/2018/2464619 Case Report Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors Alexey Youssef,1 Nawara Kasso,2 Antonio Sergio Torloni,3 Michael Stanek,4 Tomislav Dragovich,5 Mark Gimbel,6 and Fade Mahmoud 6 1Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK 2Faculty of Medicine, Tishreen University, Lattakia, Syria 3Medical Director, Stem Cell )erapy, Apheresis, and Transfusion Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 4Division of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 5Chief, Division of Medical Oncology and Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 6)e T.W. Lewis Melanoma Center of Excellence, Banner MD Anderson Cancer Center, Gilbert, AZ, USA Correspondence should be addressed to Fade Mahmoud; [email protected] Received 16 September 2018; Revised 23 November 2018; Accepted 28 November 2018; Published 20 December 2018 Academic Editor: Akimichi Ohsaka Copyright © 2018 Alexey Youssef et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ipilimumab is a monoclonal antibody that enhances the efficacy of the immune system by targeting a cytotoxic T-lymphocyte- associated protein 4 (CTLA-4), which is a protein receptor that downregulates the immune system. Nivolumab is also a hu- manized monoclonal antibody that targets another protein receptor that prevents activated T cells from attacking the cancer; this receptor is called programmed cell death 1 (PD-1). -
Prior Authorization Criteria
PRIOR AUTHORIZATION CRITERIA Last Updated 09/01/2021 This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription drug benefit. Please verify drug coverage by checking your formulary and member handbook. Additional restrictions and exclusions may apply. If you have questions, please contact Providence Health Plan Customer Service at 503-574-7500 or 1-800-878-4445 (TTY: 711). Service is available five days a week, Monday through Friday, between 8 a.m. and 6 p.m. ACTINIC KERATOSIS AGENTS MEDICATION(S) CARAC, FLUOROURACIL 0.5% CREAM, IMIQUIMOD 3.75% CREAM, IMIQUIMOD 3.75% CREAM PUMP, KLISYRI, PICATO, TOLAK, ZYCLARA COVERED USES N/A EXCLUSION CRITERIA • Treatment of basal cell carcinoma or other skin cancers REQUIRED MEDICAL INFORMATION 1. For the treatment of Actinic Keratosis (AK): Documentation of trial and failure*, contraindication or intolerance to two of the following formulary, generic topical agents: a. Diclofenac 3% gel b. 5-fluorouracil 2% or 5% cream/solution c. Imiquimod 5% cream *An adequate trial and failure is defined as failure to achieve clearance of AK lesion(s) after adherence to recommended treatment dosing and duration Reauthorization: Requires documentation of a reduction in the number and/or size of lesions of AK and medical rationale for continuing therapy beyond recommended treatment course. 1. For the treatment of external genital and perianal warts/condyloma acuminate (Zyclara® 3.75% only): Documentation of trial and failure*, contraindication, or intolerance to formulary, generic imiquimod 5% cream. -
What to Expect Following Cryosurgery “Freezing”
What to Expect Following CryoSurgery “Freezing” What is Cryosurgery? Cryosurgery is a technique for removing skin lesions that primarily involve the surface of the skin, such as warts, seborrheic keratosis, or actinic keratosis. It is a quick method of removing the lesions with minimal scarring. The liquid nitrogen needs to be applied long enough to freeze the affected skin. By freezing the skin, a blister is created underneath the lesion. Ideally, as the new skin forms underneath the blister, the abnormal skin on the roof of the blister peels off. Occasionally if the lesion is very thick (such as a large wart), only the surface is blistered off. The base or residual lesion may need to be frozen at another visit. What to Expect Over the Next Few Weeks? During Treatment – Area being treated will sting, burn and then possibly itch. Immediately After Treatment – Area will be red sore and swollen. Next Day- Blister or blood blister has formed, tenderness starts to subside. Apply a Band-Aid if necessary. 7 Days- Surface is dark red/brown and scab-like. Apply Vaseline or an antibacterial ointment if necessary. 2 to 4 Weeks- The surface starts to peel off. This may be encouraged gently during bathing, when the scab is softened. No makeup should be applied until area is fully healed. How to Take care of the Skin after Cryosurgery A Band-Aid can be used for larger blisters or blisters in areas that are more likely to be traumatized- such as fingers and toes. If the area becomes dry or crusted, an ointment (Vaseline, Aquaphor) can also be applied. -
Hair Follicle Tumors
Hair Follicle Tumors 803-808-7387 www.gracepets.com These notes are provided to help you understand the diagnosis or possible diagnosis of cancer in your pet. For general information on cancer in pets ask for our handout “What is Cancer”. Your veterinarian may suggest certain tests to help confirm or eliminate diagnosis, and to help assess treatment options and likely outcomes. Because individual situations and responses vary, and because cancers often behave unpredictably, science can only give us a guide. However, information and understanding for tumors in animals is improving all the time. We understand that this can be a very worrying time. We apologize for the need to use some technical language. If you have any questions please do not hesitate to ask us. What is this tumor? This is one of many similar tumors that arise by disordered growth of the hair follicles. These tumors are almost all benign and can be permanently cured by total surgical removal. Some occur at multiple sites within the same animal. This family of tumors grade into each other. Precise nomenclature is usually irrelevant as almost all are benign. What do we know about the cause? The reason why a particular pet may develop this, or any cancer, is not straightforward. Cancer is often seemingly the culmination of a series of circumstances that come together for the unfortunate individual. Cross Section of Skin & Hair Follicle B-catenin is required for differentiation of skin cells into hair follicles. If there is over-production of this chemical in the body, hair follicle tumors develop. -
Lumps & Bumps: Approach to Common Dermatologic Neoplasms
Case-Based Approach to Common Dermatologic Neoplasms Patrick Retterbush, MD, FAAD Mohs Surgery & Dermatologic Oncology Associate Member of the American College of Mohs Surgery Private Practice: Lockman Dermatology January 27th 2018 Disclosure of Relevant Financial Relationships • I do not have any relevant financial relationships, commercial interests, and/or conflicts of interest regarding the content of this presentation. Goals/Objectives • Recognize common benign growths • Recognize common malignant growths • Useful clues & examination for evaluating melanocytic nevi and when to be concerned for melanoma/atypical moles • How to perform a basic skin biopsy and which method/type to choose • Basic treatment/when to refer Key Questions & Physical Examination Findings for a Growth History Physical Examination • How long has the lesion been • Describing a growth present? – flat or raised? • flat – macule (<1cm) or patch (>1cm) – years, months, weeks • raised – papule (<1cm) or plaque (>1cm) – nodule if deep (majority of lesion in • Has it changed? dermis/SQ) – Size – secondary descriptive features • scaly (hyperkeratosis, retention of strateum – Shape corneum) – Color • crusty (dried serum, blood, or pus on surface) • eroded or ulcerated (partial vs. full thickness – Symptoms – pain, bleeding, itch? epidermal loss) – Over what time frame? • color (skin colored, red, pigmented, pearly) • feel (hard or soft, mobile or fixed) • PMH: • size: i.e. 6 x 4mm – prior skin cancers • Look at the rest of the skin/region of skin • SCC/BCCs vs. melanoma